It has been reported that elevated hepatic Cd36 expression was closely associated with increased hepatic and plasma triglyceride contents in both humans and rodents, which could contribute to the progression of NAFLD (32, 33). This evidence concerns the gene CD36 and metabolic dysfunction-associated steatotic liver disease.